Developer docs
API playgroundTry for free, no card

Search company profiles

GEMMABio

Full company profile

uuid0000i8s

Namestring
GEMMABio
Legal namestring
GEMMA Biotherapeutics
Websiteurl
gemmabiotx.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

GEMMABio is a Philadelphia-based biotechnology company founded in October 2024 by gene therapy pioneer Dr. James M. Wilson, focused on developing next-generation adeno-associated virus (AAV) based gene therapies for rare diseases. The company operates a portfolio of programs spanning motor neuron disorders (spinal muscular atrophy type 1 via lead asset GB221), skeletal and cardiac myopathies (Duchenne muscular dystrophy via GB703), and affiliated ultra-orphan disease work through its wholly owned spin-off Rare Therapeutics, Inc. (RareTx). Core technical differentiators include a novel myotropic AAV capsid (GCap104) for muscle-directed delivery, a de-immunized miniature utro/dystrophin hybrid transgene, and a modified SMN1 expression cassette delivered via intra-cisterna magna injection to reduce overexpression-related toxicity. Lead program GB221 is in the CHARISMA Phase 1/2 trial across U.S. and Brazilian sites, with GB703 currently in preclinical development and affiliated MVX-220 (Angelman syndrome) holding FDA Orphan Drug Designation.

The company is pre-revenue and clinical-stage. Anticipated revenue mechanics rely on one-time gene therapy product sales at premium pricing typical of rare disease AAV therapies (>$2M per treatment), supplemented by partnership milestone payments, royalties, and co-development arrangements. To date, GEMMABio has secured a $34M seed round (December 2024) co-led by Double Point Ventures, Bioluminescence Ventures, and Earlybird Venture Capital, plus a $100M strategic partnership with Brazil's Fiocruz for regional manufacturing and Latin American access. International expansion is further supported by UAE partnerships with the Department of Health – Abu Dhabi, M42, and PureHealth, positioning the company to pursue a multi-jurisdictional, emerging-market-enabled commercialization model that differentiates from U.S./EU-centric gene therapy peers.

Short descriptiontext

GEMMABio is a Philadelphia-based biotech founded in 2024 by gene therapy pioneer Dr. James M. Wilson that develops next-generation AAV-based gene therapies for rare diseases, with lead programs in spinal muscular atrophy type 1 and Duchenne muscular dystrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, rare disease therapeutics, AAV vector technology, neuromuscular disease treatment, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Product Sales
TypeOne Time License
Description

One-time gene therapy treatments for rare diseases. GEMMABio is developing transformative, next-generation AAV-based gene therapies delivered as single treatments. Revenue would be generated through product sales upon regulatory approval.

gemmabiotx.com
2Partnership and Licensing Agreements
TypeLicensing Royalties
Description

Strategic partnerships with international entities such as the $100M agreement with Fiocruz for regional manufacturing and access expansion in Latin America. May include milestone payments, royalties, and co-development arrangements.

technical.ly
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GEMMABio develops next-generation AAV-based gene therapies for rare diseases, with clinical-stage programs for spinal muscular atrophy type 1 (GB221, currently in the CHARISMA Phase 1/2 trial in the U.S. and Brazil) and Duchenne muscular dystrophy (GB703, preclinical). The company designs engineered AAV capsids (GCap104), de-immunized transgenes, and innovative delivery methods (intra-cisterna magna injection) intended as transformative single-dose treatments, and partners with international organizations such as Fiocruz (Brazil) and UAE health authorities to enable local manufacturing and global access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • GB221 demonstrated over 50% survival at 120 days compared to under 15 days in untreated SMA1 models in preclinical studies.
+1 more record
Product overview1 text field

GEMMABio is a biotechnology company developing a portfolio of gene therapies for rare diseases using next-generation AAV (adeno-associated virus) technology. The company's programs span motor neuron disorders and skeletal/cardiomyopathies. Core products include GB221 (clinical-stage gene therapy for SMA1, currently in CHARISMA Phase 1/2 trial), GB703 (preclinical gene therapy for DMD using a novel GCap104 capsid), and affiliated program MVX-220 (gene therapy for Angelman Syndrome). GEMMABio's platform is built on 40 years of AAV research led by founder Dr. James M. Wilson.

Product and service2 records
1GB221
CategoryClinical-stage gene therapy program
Description

Investigational next-generation AAV-based gene therapy for spinal muscular atrophy type 1 (SMA1). GB221 consists of an AAV vector encasing a codon-optimized SMN1 gene in a modified transgene expression cassette designed to reduce overexpression-related toxicities and sensory neurotoxicity. The therapy is delivered via intra-cisterna magna (ICM) injection into the cerebrospinal fluid to enable targeted motor neuron transduction without systemic toxicity, and is intended for pediatric SMA1 patients with high unmet medical need.

2GB703
CategoryPreclinical gene therapy program
Description

Investigational AAV-based gene therapy for Duchenne muscular dystrophy (DMD). GB703 is designed to express a micro-utro/dystrophin hybrid gene in muscle cells using GEMMABio's proprietary myotropic AAV capsid (GCap104) and a de-immunized miniaturized transgene. It is delivered intravenously and engineered to provide broad mutation coverage across DMD patients, including those with N-terminal region deletions, and is intended as a single-dose transformative treatment for Duchenne muscular dystrophy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

$100 million partnership agreement with Brazil's leading health research institute under the Ministry of Health. The partnership aims to expand research and access to gene therapies for rare diseases in Latin America, including local manufacturing capabilities and regional clinical trial operations. Brazil serves as a regional hub for GEMMABio's clinical activities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Regulatory body of the Healthcare Sector in Abu Dhabi, UAE, partnering to advance gene therapies for children with spinal muscular atrophy and other rare diseases in the region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global health champion headquartered in Abu Dhabi powered by AI, technology, and genomics to advance health innovation. Partnership focuses on collaborative efforts in gene therapy development and deployment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The largest healthcare group in the UAE with expanding global operations, supporting GEMMABio's gene therapy access initiatives in the Middle East region.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis commercializes Zolgensma, the first FDA-approved AAV gene therapy for SMA, which directly competes with GEMMABio's GB221 in SMA1. As a global pharmaceutical incumbent with established SMA commercial infrastructure, Novartis is the dominant comparator for any next-generation SMA1 gene therapy.

TypeDirect peer
Description

Sarepta develops Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy, directly competing with GEMMABio's GB703 program. Both target DMD via AAV delivery of micro-dystrophin constructs, making Sarepta the most direct competitor in DMD gene therapy.

TypeDirect peer
Description

Regenxbio is a clinical-stage AAV gene therapy company developing treatments for rare diseases including SMA (RGX-202) and DMD, directly overlapping with GEMMABio's portfolio. Both companies leverage proprietary AAV capsid technologies developed within the broader AAV research community.

TypeEmerging player
Description

Passage Bio is an AAV gene therapy company for rare CNS disorders that was founded by Dr. James Wilson and licensed technology from Penn's Gene Therapy Program — making it a closely related entity with shared scientific lineage. Both target CNS-delivered AAV gene therapies for rare pediatric diseases.

TypeDirect peer
Description

uniQure is a clinical-stage AAV gene therapy company with an approved product (Hemgenix for hemophilia B) and pipeline in rare diseases. Both companies share the AAV platform approach and target monogenic rare disease populations with one-time curative therapies.

TypeDirect peer
Description

Solid Biosciences develops AAV gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases, with programs in clinical development. Both companies target DMD via AAV micro-dystrophin delivery and share similar competitive dynamics.

TypeEmerging player
Description

Taysha is a clinical-stage AAV gene therapy company focused on rare CNS diseases. Both companies pursue AAV gene therapy for rare monogenic neurological disorders using similar delivery approaches and target similar patient populations.

TypeBroad incumbent
Description

BioMarin is an established rare disease biopharmaceutical company with a gene therapy pipeline (Roctavian for hemophilia A) and broader rare disease franchise. As a larger player with commercial infrastructure, BioMarin represents both a potential acquirer and competitive benchmark.

TypeDirect peer
Description

Rocket Pharmaceuticals develops AAV and lentiviral gene therapies for rare pediatric diseases including hematological and cardiac disorders. Both companies target ultra-rare pediatric populations with one-time gene therapy approaches.

TypeEmerging player
Description

Krystal Biotech commercializes Vyjuvek, an approved topical gene therapy for dystrophic epidermolysis bullosa (rare disease), and pursues additional rare disease programs. Krystal represents an emerging commercial-stage AAV gene therapy peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GEMMABio

Gene Therapygemmabiotx.com

GEMMABio is a Philadelphia-based biotech founded in 2024 by gene therapy pioneer Dr. James M. Wilson that develops next-generation AAV-based gene therapies for rare diseases, with lead programs in spinal muscular atrophy type 1 and Duchenne muscular dystrophy.

What GEMMABio does

GEMMABio is a Philadelphia-based biotechnology company founded in October 2024 by gene therapy pioneer Dr. James M. Wilson, focused on developing next-generation adeno-associated virus (AAV) based gene therapies for rare diseases. The company operates a portfolio of programs spanning motor neuron disorders (spinal muscular atrophy type 1 via lead asset GB221), skeletal and cardiac myopathies (Duchenne muscular dystrophy via GB703), and affiliated ultra-orphan disease work through its wholly owned spin-off Rare Therapeutics, Inc. (RareTx). Core technical differentiators include a novel myotropic AAV capsid (GCap104) for muscle-directed delivery, a de-immunized miniature utro/dystrophin hybrid transgene, and a modified SMN1 expression cassette delivered via intra-cisterna magna injection to reduce overexpression-related toxicity. Lead program GB221 is in the CHARISMA Phase 1/2 trial across U.S. and Brazilian sites, with GB703 currently in preclinical development and affiliated MVX-220 (Angelman syndrome) holding FDA Orphan Drug Designation.

The company is pre-revenue and clinical-stage. Anticipated revenue mechanics rely on one-time gene therapy product sales at premium pricing typical of rare disease AAV therapies (>$2M per treatment), supplemented by partnership milestone payments, royalties, and co-development arrangements. To date, GEMMABio has secured a $34M seed round (December 2024) co-led by Double Point Ventures, Bioluminescence Ventures, and Earlybird Venture Capital, plus a $100M strategic partnership with Brazil's Fiocruz for regional manufacturing and Latin American access. International expansion is further supported by UAE partnerships with the Department of Health – Abu Dhabi, M42, and PureHealth, positioning the company to pursue a multi-jurisdictional, emerging-market-enabled commercialization model that differentiates from U.S./EU-centric gene therapy peers.

GEMMABio firmographics

Firmographics
Name
GEMMABio
Legal name
GEMMA Biotherapeutics
Website
https://gemmabiotx.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
GEMMABio is a Philadelphia-based biotech founded in 2024 by gene therapy pioneer Dr. James M. Wilson that develops next-generation AAV-based gene therapies for rare diseases, with lead programs in spinal muscular atrophy type 1 and Duchenne muscular dystrophy.
Ownership category
akta.pro rank

GEMMABio industry classification

Industry
Product category
Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Rare disease therapeutics
  • AAV vector technology
  • Neuromuscular disease treatment
  • Clinical-stage biotechnology

Where GEMMABio is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices2 records

Markets served

GEMMABio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Gene Therapy Product Sales: One-time gene therapy treatments for rare diseases. GEMMABio is developing transformative, next-generation AAV-based gene therapies delivered as single treatments. Revenue would be generated through product sales upon regulatory approval.
  2. Partnership and Licensing Agreements: Strategic partnerships with international entities such as the $100M agreement with Fiocruz for regional manufacturing and access expansion in Latin America. May include milestone payments, royalties, and co-development arrangements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

GEMMABio product offering

Product offering

Core offering

GEMMABio develops next-generation AAV-based gene therapies for rare diseases, with clinical-stage programs for spinal muscular atrophy type 1 (GB221, currently in the CHARISMA Phase 1/2 trial in the U.S. and Brazil) and Duchenne muscular dystrophy (GB703, preclinical). The company designs engineered AAV capsids (GCap104), de-immunized transgenes, and innovative delivery methods (intra-cisterna magna injection) intended as transformative single-dose treatments, and partners with international organizations such as Fiocruz (Brazil) and UAE health authorities to enable local manufacturing and global access.

Product overview

GEMMABio is a biotechnology company developing a portfolio of gene therapies for rare diseases using next-generation AAV (adeno-associated virus) technology. The company's programs span motor neuron disorders and skeletal/cardiomyopathies. Core products include GB221 (clinical-stage gene therapy for SMA1, currently in CHARISMA Phase 1/2 trial), GB703 (preclinical gene therapy for DMD using a novel GCap104 capsid), and affiliated program MVX-220 (gene therapy for Angelman Syndrome). GEMMABio's platform is built on 40 years of AAV research led by founder Dr. James M. Wilson.

Differentiator

Problem solved

Functional benefit

Products and services

  • GB221 Investigational next-generation AAV-based gene therapy for spinal muscular atrophy type 1 (SMA1). GB221 consists of an AAV vector encasing a codon-optimized SMN1 gene in a modified transgene expression cassette designed to reduce overexpression-related toxicities and sensory neurotoxicity. The therapy is delivered via intra-cisterna magna (ICM) injection into the cerebrospinal fluid to enable targeted motor neuron transduction without systemic toxicity, and is intended for pediatric SMA1 patients with high unmet medical need.
  • GB703 Investigational AAV-based gene therapy for Duchenne muscular dystrophy (DMD). GB703 is designed to express a micro-utro/dystrophin hybrid gene in muscle cells using GEMMABio's proprietary myotropic AAV capsid (GCap104) and a de-immunized miniaturized transgene. It is delivered intravenously and engineered to provide broad mutation coverage across DMD patients, including those with N-terminal region deletions, and is intended as a single-dose transformative treatment for Duchenne muscular dystrophy.

Quantifiable outcome

  • GB221 demonstrated over 50% survival at 120 days compared to under 15 days in untreated SMA1 models in preclinical studies.
  • +1 more outcomes

Companies that use GEMMABio

Customer profile

Segments1 record

Ideal customer profiles2 records

GEMMABio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

GEMMABio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • Fiocruz (Oswaldo Cruz Foundation)flagshipStrategic or Co-development Partner · 8 October 2024$100 million partnership agreement with Brazil's leading health research institute under the Ministry of Health. The partnership aims to expand research and access to gene therapies for rare diseases in Latin America, including local manufacturing capabilities and regional clinical trial operations. Brazil serves as a regional hub for GEMMABio's clinical activities.
  • Department of Health - Abu DhabicoreStrategic or Co-development PartnerRegulatory body of the Healthcare Sector in Abu Dhabi, UAE, partnering to advance gene therapies for children with spinal muscular atrophy and other rare diseases in the region.
  • M42coreStrategic or Co-development PartnerGlobal health champion headquartered in Abu Dhabi powered by AI, technology, and genomics to advance health innovation. Partnership focuses on collaborative efforts in gene therapy development and deployment.
  • PureHealthcoreStrategic or Co-development PartnerThe largest healthcare group in the UAE with expanding global operations, supporting GEMMABio's gene therapy access initiatives in the Middle East region.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

GEMMABio competitors and assessment

Company assessment

Broad incumbents

  • Novartis (Zolgensma): Novartis commercializes Zolgensma, the first FDA-approved AAV gene therapy for SMA, which directly competes with GEMMABio's GB221 in SMA1. As a global pharmaceutical incumbent with established SMA commercial infrastructure, Novartis is the dominant comparator for any next-generation SMA1 gene therapy.
  • BioMarin Pharmaceutical: BioMarin is an established rare disease biopharmaceutical company with a gene therapy pipeline (Roctavian for hemophilia A) and broader rare disease franchise. As a larger player with commercial infrastructure, BioMarin represents both a potential acquirer and competitive benchmark.

Direct peers

  • Sarepta Therapeutics: Sarepta develops Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy, directly competing with GEMMABio's GB703 program. Both target DMD via AAV delivery of micro-dystrophin constructs, making Sarepta the most direct competitor in DMD gene therapy.
  • Regenxbio: Regenxbio is a clinical-stage AAV gene therapy company developing treatments for rare diseases including SMA (RGX-202) and DMD, directly overlapping with GEMMABio's portfolio. Both companies leverage proprietary AAV capsid technologies developed within the broader AAV research community.
  • uniQure: uniQure is a clinical-stage AAV gene therapy company with an approved product (Hemgenix for hemophilia B) and pipeline in rare diseases. Both companies share the AAV platform approach and target monogenic rare disease populations with one-time curative therapies.
  • Solid Biosciences: Solid Biosciences develops AAV gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases, with programs in clinical development. Both companies target DMD via AAV micro-dystrophin delivery and share similar competitive dynamics.
  • Rocket Pharmaceuticals: Rocket Pharmaceuticals develops AAV and lentiviral gene therapies for rare pediatric diseases including hematological and cardiac disorders. Both companies target ultra-rare pediatric populations with one-time gene therapy approaches.

Emerging players

  • Passage Bio: Passage Bio is an AAV gene therapy company for rare CNS disorders that was founded by Dr. James Wilson and licensed technology from Penn's Gene Therapy Program — making it a closely related entity with shared scientific lineage. Both target CNS-delivered AAV gene therapies for rare pediatric diseases.
  • Taysha Gene Therapies: Taysha is a clinical-stage AAV gene therapy company focused on rare CNS diseases. Both companies pursue AAV gene therapy for rare monogenic neurological disorders using similar delivery approaches and target similar patient populations.
  • Krystal Biotech: Krystal Biotech commercializes Vyjuvek, an approved topical gene therapy for dystrophic epidermolysis bullosa (rare disease), and pursues additional rare disease programs. Krystal represents an emerging commercial-stage AAV gene therapy peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

GEMMABio social profiles

Digital presence

GEMMABio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GEMMABio leadership team

Management profile

Number of profiles

Profiles6 records

GEMMABio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GEMMABio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GEMMABio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GEMMABio

What does GEMMABio do?

GEMMABio develops next-generation AAV-based gene therapies for rare diseases, with clinical-stage programs for spinal muscular atrophy type 1 (GB221, currently in the CHARISMA Phase 1/2 trial in the U.S. and Brazil) and Duchenne muscular dystrophy (GB703, preclinical). The company designs engineered AAV capsids (GCap104), de-immunized transgenes, and innovative delivery methods (intra-cisterna magna injection) intended as transformative single-dose treatments, and partners with international organizations such as Fiocruz (Brazil) and UAE health authorities to enable local manufacturing and global access.

Is GEMMABio a public or private company?

GEMMABio is a private company. It is classified as venture growth investor backed and is currently operating.

When was GEMMABio founded?

GEMMABio was founded in 2024. It employs 51 to 100 people.

Where is GEMMABio based?

GEMMABio is headquartered in Philadelphia, United States, in the North America region.

How does GEMMABio make money?

Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are partnership and Licensing Agreements.

Who are GEMMABio's main competitors?

Broad incumbents on record are Novartis (Zolgensma) and BioMarin Pharmaceutical. Direct peers are Sarepta Therapeutics, Regenxbio, uniQure, Solid Biosciences and Rocket Pharmaceuticals. Emerging players are Passage Bio, Taysha Gene Therapies and Krystal Biotech.

Does GEMMABio have an API?

No public API is recorded for GEMMABio.

What industry is GEMMABio in?

GEMMABio's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WHYYPhiladelphia labs get funds to treat rare diseases in 5 yearsThe federal government awarded research funding to the Children’s Hospital of Philadelphia and GEMMABio to develop scalable gene therapies for rare diseases, with a mandate to begin human trials within three years. This initiative aims to overcome current limitations by using lipid nanoparticles instead of viruses for delivery, addressing conditions such as Maple syrup urine disease and homozygous familial hypercholesterolemia. The project seeks to fill a gap left by traditional pharmaceutical companies by creating efficient, one-time treatments that can be produced at scale.The Philadelphia InquirerFeds award $43 million to Philly gene therapy research to advance treatments for rare diseasesThe U.S. government awarded $43 million in funding to researchers at the Children’s Hospital of Philadelphia and GEMMABio, a University of Pennsylvania spinout, to advance gene therapies for rare genetic diseases. The funding supports CHOP's development of a scalable platform for treating liver-related conditions and GEMMABio's AI-driven design of base editors for specific rare disorders.BioSpaceGEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver DiseasesGEMMABio received ARPA-H funding to develop AI-designed base-editing products for rare liver diseases, partnering with Profluent Bio. The project targets four founder mutations in homozygous familial hypercholesterolemia and maple syrup urine disease using lipid nanoparticle delivery. The collaboration aims to establish a proof-of-concept for scalable, low-cost personalized gene editing.BostonGlobe.comARPA-H launches $160 million effort to develop custom gene editing drugsARPA-H, the US health research "moonshot" agency, announced Thursday it will spend up to $160 million on a program called THRIVE to develop custom gene editing treatments for rare diseases. The program will back seven different teams pursuing treatments for conditions affecting different organ systems, including metabolic disorders, immune disorders, blood disorders, pediatric epilepsies, genetic heart disease, blood vessel diseases, and skin diseases. The funded institutions include Children's Hospital of Philadelphia, UC Berkeley with the Innovative Genomics Institute, St. Jude Children's Research Hospital, Broad Institute, GemmaBio with Profluent Bio, Massachusetts General Hospital, and Stanford University.AijournGEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver DiseasesGEMMABio has been awarded funding by the U.S. Advanced Research Projects Agency for Health (ARPA-H) under the THRIVE program to develop AI-designed base-editing therapies for two rare monogenic liver diseases: homozygous familial hypercholesterolemia and maple syrup urine disease. The RAPID project will be conducted in partnership with Profluent Bio, which will provide its frontier AI protein language models and base editors, while GEMMABio delivers the therapies via lipid nanoparticles to target hepatocytes. The collaboration also involves a multi-regulator network coordinated by the UK's MHRA and aims to establish a scalable, low-cost base-editing platform that could accelerate personalized genetic medicines from concept to clinic.PR NewswireGEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver DiseasesGEMMABio has been awarded funding by the Advanced Research Projects Agency for Health (ARPA-H) under its THRIVE program to support development of AI-designed base-editing systems for two rare monogenic liver diseases. The RAPID project will be conducted in partnership with Profluent Bio, which will provide its frontier AI models and base editors for delivery via lipid nanoparticles targeting hepatocytes. The collaboration aims to develop treatments for founder mutations causing homozygous familial hypercholesterolemia and maple syrup urine disease, potentially establishing a cost-effective and scalable approach to personalized gene editing for rare diseases.AdvfnGEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver DiseasesGEMMABio has been awarded funding by the Advanced Research Projects Agency for Health (ARPA-H) under its THRIVE program to develop AI-designed base-editing therapies for two rare monogenic liver diseases: homozygous familial hypercholesterolemia and maple syrup urine disease. The project, conducted in partnership with Profluent Bio, will use lipid nanoparticle-delivered mRNA-encoded base editors targeting four founder-type mutations across the two diseases. The initiative includes regulatory collaboration coordinated by the UK's MHRA and aims to establish a scalable, low-cost personalized gene editing platform for rare disease populations.PR NewswireGEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual MGEMMABio announced preclinical data for GB703, a novel gene therapy candidate for Duchenne muscular dystrophy (DMD), at the ASGCT 2026 Annual Meeting, featuring a de-immunized miniature transgene and a novel myotropic AAV capsid (GCap104) designed to broaden mutation coverage and improve muscle delivery. The company also presented preclinical data for GB221, its next-generation investigational gene therapy for spinal muscular atrophy type 1 (SMA1), which demonstrated over 50% survival at 120 days compared to under 15 days in untreated models. The CHARISMA Phase 1/2 clinical trial for GB221 in SMA1 is underway in Brazil and progressing on schedule.PR NewswireGEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)GEMMABio announced that the first patient has been dosed in the Phase 1/2 CHARISMA clinical trial of GB221, an investigational next-generation gene therapy for Spinal Muscular Atrophy Type 1 delivered directly to the cerebrospinal fluid via intracisterna-magna injection. The trial is being conducted in Brazil through a public-private partnership with Fiocruz, with the U.S. FDA having granted GB221 rare pediatric disease designation, making GEMMABio eligible to receive a priority review voucher upon approval. The therapy was developed using proprietary CNS platform technology licensed from the University of Pennsylvania.PR NewswireGEMMABio Announces Clinical Trial Authorization for New SMA1 Gene TherapyGEMMABio announced that ANVISA, Brazil's health regulatory agency, has authorized a clinical trial for GB221, the company's novel gene therapy for spinal muscular atrophy type 1 (SMA1), with first patient dosing expected within the next few months. GB221 uses an AAVhu68 virus encasing a functional SMN1 gene, delivered via intra-cisterna magna injection to the cerebrospinal fluid, and demonstrated promising preclinical safety and efficacy data in mouse models and non-human primates. The trial will be conducted under GEMMABio's partnership with Brazil's Oswaldo Cruz Foundation (Fiocruz), with three clinical sites planned in Brazil as a regional hub for Latin America, alongside a separate Middle East site anticipated to open in 2026.